Digitala Vetenskapliga Arkivet

Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs
Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Pharm & Pharmaceut Sci, Dublin, Ireland..ORCID-id: 0000-0003-0730-1829
Mylan Global Resp Grp, Sandwich, Kent, England..ORCID-id: 0000-0001-6210-8461
Univ Poitiers, CHU Poitiers, UFR Med Pharm, Inserm,U1070, Poitiers, France..
GlaxoSmithKline Medicines Res Ctr, Refractory Resp Inflammat DPU, Stevenage, Herts, England..
Vise andre og tillknytning
2017 (engelsk)Inngår i: Journal of Pharmaceutical Sciences, ISSN 0022-3549, E-ISSN 1520-6017, Vol. 106, nr 9, s. 2234-2244Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

The School of Pharmacy and Pharmaceutical Sciences at Trinity College Dublin hosted the "1st Workshop on Drug Transporters in the Lungs" in September 2016 to discuss the impact of transporters on pulmonary drug disposition and their roles as drug targets in lung disease. The workshop brought together about 30 scientists from academia and pharmaceutical industry from Europe and Japan and addressed the primary questions: What do we know today, and what do we need to know tomorrow about transporters in the lung? The 3 themes of the workshop were: (1) techniques to study drug transporter expression and actions in the lungs; (2) drug transporter effects on pulmonary pharmacokinetics-case studies; and (3) transporters as drug targets in lung disease. Some of the conclusions of the workshop were: suitable experimental models that allow studies of transporter effects are available; data from these models convincingly show a contribution of both uptake and efflux transporters on pulmonary drug disposition; the effects of transporters on drug lung PK is now better conceptualized; some transporters are associated with lung diseases. However, more work is needed to establish which of the available models best translate to the clinical situation.

sted, utgiver, år, opplag, sider
2017. Vol. 106, nr 9, s. 2234-2244
Emneord [en]
absorption, computational ADME, efflux pumps, in vitro models, organic cation transporters, P-glycoprotein, peptide transporters, pulmonary delivery/absorption, ABC transporters, organic anion-transporting polypeptide transporters
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-344532DOI: 10.1016/j.xphs.2017.04.011ISI: 000417339900010PubMedID: 28416418OAI: oai:DiVA.org:uu-344532DiVA, id: diva2:1188419
Tilgjengelig fra: 2018-03-07 Laget: 2018-03-07 Sist oppdatert: 2018-03-07bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Søk i DiVA

Av forfatter/redaktør
Ehrhardt, CarstenBackman, PerFridén, Markus
Av organisasjonen
I samme tidsskrift
Journal of Pharmaceutical Sciences

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 106 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf